Cameron Brady Haas

Dr. Cameron Brady Haas

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in The Lancet HIV
Verified
Journal Article
Closed access
CHCameron Brady Haas
Cameron Brady Haas
EEEric A Engels
Eric A Engels
MHMarie-Josèphe Horner
Marie-Josèphe Horner
NFNeal D Freedman
Neal D Freedman
QLQianlai Luo
Qianlai Luo
MSMeredith S Shiels
Meredith S Shiels

22 February 2022 in Endocrinology
Verified
Journal Article
Open access
PDF file
CHCameron Brady Haas
Cameron Brady Haas
LHLi Hsu
Li Hsu
JLJohanna W Lampe
Johanna W Lampe
KWKaren J Wernli
Karen J Wernli
SLSara Lindström
Sara Lindström
Objective Concentrations of circulating sex hormones have been associated with a variety of diseases in women and are strongly influenced by menopausal status. We investigated the genetic architectures of circulating concentrations of estradiol, testosterone, and SHBG by menopausal status in women of European and African ancestry. Methods Using data on 229 966 women from the UK Biobank, we conducted genome-wide association studies (GWASs) of circulating concentrations of estradiol, testosterone, and SHBG in premenopausal and postmenopausal women. We tested for evidence of heterogeneity of genetic effects by menopausal status and genetic ancestry. We conducted gene-based enrichment analyses to identify tissues in which genes with GWAS-enriched signals were expressed. Results We identified 4 loci (5q35.2, 12q14.3, 19q13.42, 20p12.3) that were associated with detectable concentrations of estradiol in both pre- and postmenopausal women of European ancestry. Heterogeneity analysis identified 1 locus for testosterone (7q22.1) in the CYP3A7 gene and 1 locus that was strongly associated with concentrations of SHBG in premenopausal women only (10q15.1) near the AKR1C4 gene. Gene-based analysis of testosterone revealed evidence of enrichment of GWAS signals in genes expressed in adipose tissue for postmenopausal women. We did not find any evidence of ancestry-specific genetic effects for concentrations of estradiol, testosterone, or SHBG. Conclusions We identified specific loci that showed genome-wide significant evidence of heterogeneity by menopausal status for testosterone and SHBG. We also observed support for a more prominent role of genetic variants located near genes expressed in adipose tissue in determining testosterone concentrations among postmenopausal women.

1 August 2025 in JAMA Oncology
Verified
Journal Article
Closed access
CHCameron Brady Haas
Cameron Brady Haas
JMJennifer K. McGee-Avila
Jennifer K. McGee-Avila
QLQianlai Luo
Qianlai Luo
RPRuth M. Pfeiffer
Ruth M. Pfeiffer
SGSusan Gershman
Susan Gershman
MSMeredith S. Shiels
Meredith S. Shiels
Importance: People with HIV are living longer due to improvements in antiretroviral therapy over the last 2 decades. Current age-specific estimates of cancer risk among people with HIV may inform cancer prevention and clinical guidelines for this population.Objective: To estimate cancer incidence rates (IRs) using a population-based linkage of HIV and cancer registries.Design, Setting, and Participants: This population-based cohort study used data from 12 US states, Washington, DC, and Puerto Rico from 2001 to 2019. People with HIV and the general population in the HIV/AIDS Cancer Match Study were included in the analysis, which occurred between October 2023 and December 2024.Main Outcomes and Measures: Age-standardized IRs (per 100 000 person-years) were calculated across calendar periods (2001 to 2004, 2005 to 2009, 2010 to 2014, and 2015 to 2019) and incidence rate ratios (IRRs) across calendar periods using adjusted Poisson regression. Standardized incidence ratios (SIRs) were estimated for 2010 to 2014 and 2015 to 2019, and age group–specific cancer incidence and SIRs were estimated for 2010 to 2019.Results: The analysis included 7.2 million person-years among 847 107 people with HIV (5.3 million person-years among males [73%]). Comparing years 2015 to 2019 to years 2010 to 2014, incidence of diffuse large B-cell lymphoma (DLBCL) decreased 23% (IRR, 0.77; 95% CI, 0.70-0.84), Kaposi sarcoma (KS) decreased 24% (IRR, 0.76; 95% CI, 0.69-0.84), Hodgkin lymphoma decreased 25% (IRR, 0.75; 95% CI, 0.65-0.86), and cancers of the lung decreased 17% (IRR, 0.83; 95% CI, 0.77-0.90) and liver decreased 25% (IRR, 0.75; 95% CI, 0.67-0.84). Among people with HIV aged 70 to 84 years, IRs were highest for cancers of the prostate (448.01; 95% CI, 404.26-495.20), lung (269.79; 95% CI, 240.86-301.24), female breast (202.29; 95% CI, 155.79-258.32), liver (82.82; 95% CI, 67.16-101.03), and colon (107.57; 95% CI, 89.61-128.08), exceeding the IRs for DLBCL (41.83; 95% CI, 30.95-55.31) and KS (15.37; 95% CI, 9.11-24.29). From 2015 to 2019, risk remained significantly elevated in people with HIV for several cancer types, including KS (SIR, 213.87; 95% CI, 198.81-229.73), Hodgkin lymphoma (SIR, 6.29; 95% CI, 5.68-6.94), DLBCL (SIR, 5.25; 95% CI, 5.25-6.01), cancers of the anus (SIR, 17.07; 95% CI, 16.01-18.17), vulva (SIR, 11.40; 95% CI, 9.60-13.44), liver (SIR, 1.89; 95% CI, 1.74-2.05), and lung (SIR, 1.59; 95% CI, 1.51-1.68). For nearly all these cancers, SIRs significantly declined with increasing age.Conclusions and Relevance: In this cohort study, significant declines in the incidence and relative risk for cancers among people with HIV demonstrate continued progress in HIV treatment and cancer prevention. These estimates may provide insight into the priorities for prevention and early detection of cancer as the population of people with HIV enters ages with greater risk for cancer.

17 April 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CHCameron Brady Haas
Cameron Brady Haas
LNLarissa Nekhlyudov
Larissa Nekhlyudov
JLJanie M. Lee
Janie M. Lee
SJSara H. Javid
Sara H. Javid
MBMary Bush
Mary Bush
KWKaren J. Wernli
Karen J. Wernli

26 August 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
CHCameron Brady Haas
Cameron Brady Haas
EEEric A Engels
Eric A Engels
JPJoel M Palefsky
Joel M Palefsky
MCMegan A Clarke
Megan A Clarke
AKAimée R Kreimer
Aimée R Kreimer
MSMeredith S Shiels
Meredith S Shiels
Background: Anal intraepithelial neoplasia grade III is a precursor to squamous cell carcinoma of the anus for which rates are nearly 20-fold higher in people with HIV than in the general population in the United States. We describe trends in anal intraepithelial neoplasia grade III diagnosis and risk of squamous cell carcinoma of the anus following anal intraepithelial neoplasia grade III by HIV status and sex. Methods: We used data from a population-based linkage between cancer and HIV registries in 11 US states; Puerto Rico; and Washington, DC, during 1996-2019. We identified all individuals with a diagnosis of anal intraepithelial neoplasia grade III and determined their HIV status. We estimated the average annual percentage change of anal intraepithelial neoplasia grade III using Poisson regression stratified by HIV status and sex. We estimated the 5-year cumulative incidence of squamous cell carcinoma of the anus following an anal intraepithelial neoplasia grade III diagnosis stratified by sex, HIV status, and prior AIDS diagnosis. Results: Among people with HIV, average annual percentage changes for anal intraepithelial neoplasia grade III were 15% (95% confidence interval [CI] = 12% to 17%) per year among females and 12% (95% CI = 11% to 14%) among males. Average annual percentage changes for those without HIV were 8% (95% CI = 7% to 8%) for females and 8% (95% CI = 6% to 9%) for males. Among people with HIV, a prior AIDS diagnosis was associated with a 2.7-fold (95% CI = 2.23 to 3.40) and 1.9-fold (95% CI = 1.72 to 2.02) increased risk of anal intraepithelial neoplasia grade III diagnosis for females and males, respectively. Five-year cumulative incidence of squamous cell carcinoma of the anus following anal intraepithelial neoplasia grade III for people with HIV with a prior AIDS diagnosis were 3.4% and 3.7% for females and males, respectively. Conclusions: Rates of anal intraepithelial neoplasia grade III diagnoses have increased since 1996, particularly for people with HIV, likely influenced by increased screening. A prior AIDS diagnosis was strongly associated with risk of anal intraepithelial neoplasia grade III diagnosis.

3 July 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
CHCameron Brady Haas
Cameron Brady Haas
EEEric A Engels
Eric A Engels
MHMarie-Josèphe Horner
Marie-Josèphe Horner
RPRuth M Pfeiffer
Ruth M Pfeiffer
QLQianlai Luo
Qianlai Luo
MSMeredith S Shiels
Meredith S Shiels
Treatment of screen-detected anal high-grade squamous intraepithelial lesions has been shown to effectively reduce the incidence of invasive anal cancer in people with HIV. We provide population-based estimates of cumulative incidence of anal cancer by risk group and age at HIV or AIDS diagnosis. The 0- to 10-year cumulative incidence of anal cancer for men who have sex with men and are younger than 30 years of age at HIV diagnosis was 0.17% (95% confidence interval [CI] = 0.13% to 0.20%) compared with 0.04% (95% CI = 0.02% to 0.06%) in other men and 0.03% (95% CI = 0.01% to 0.04%) in women. For men who have sex with men and have a diagnosis of AIDS and are younger than 30 years of age, the 0- to 10-year cumulative incidence was 0.35% (95% CI = 0.28% to 0.41%). Among people with HIV, men who have sex with men are at the greatest risk of anal cancer, and those with a diagnosis of AIDS had higher risk than those without AIDS. These estimates may inform recommendations for priority populations that could benefit most from anal cancer screening and treatment.